-
2024-516608-40-00
10
2022-02-23
Caucasian paediatric kidney transplant recipients
-
2024-511071-16-00
3
2022-02-10
Solid Tumours
-
2024-514570-43-00
5
2022-01-24
Renal cell carcinoma
-
2023-509996-18-00
1
2022-01-18
Locally advanced and metastatic solid tumor including non-small cell l
-
2023-507688-20-00
5
2021-12-03
Participants with completely resected Stage III or Stage IV melanoma
-
2024-510762-16-00
4
2021-11-30
Metastatic head and neck squamous cell carcinoma (HNSCC)
-
2023-509696-17-00
6
2021-11-05
Chronic Thromboembolic Pulmonary Hypertension
-
2022-500881-80-00
5
2021-10-29
Chronic Heart Failure With Reduced Ejection Fraction
-
2024-511066-36-00
5
2021-10-13
Light Chain (AL) Amyloidosis
-
2023-510057-41-00
5
2021-10-06
Patients With Homozygous and Heterozygous Familial Hypercholesterolemi
-
2024-512879-13-00
5
2021-09-23
Neovascular age-related macular degeneration (wet AMD)
-
2023-505284-36-00
4
2021-09-13
Advanced solid tumors
-
2024-512622-29-00
7
2021-09-10
Cholangiocarcinoma (CCA) and Other Advanced Solid Tumors
-
2023-510162-27-00
4
2021-08-18
Chronic venous ulcers (CVU)
-
2022-500877-15-00
10
2021-06-25
Pulmonary arterial hypertension (PAH) in one of the following groups:
-
2023-505786-88-00
5
2021-04-25
Severe and inadequately controlled asthma
-
2023-509513-36-00
4
2021-03-24
Melanoma (Stage III and IV)
-
2024-513075-40-00
4
2021-03-01
Relapsed or refractory AL amyloidosis
-
2024-516431-27-00
6
2021-02-23
Wilson’s Disease
-
2024-512652-38-00
4
2021-01-25
Cutaneous Squamous Cell Carcinoma
-
2023-508443-40-00
5
2020-12-18
Lung Cancer, Non-Small Cell
-
2023-505492-68-00
4
2020-10-06
Primary Dilated Cardiomyopathy Due to Either MYH7 o TTN Variants
-
2022-502480-38-00
5
2020-09-09
Non−small cell lung cancer (NSCLC)
-
2023-507222-17-00
5
2020-07-24
Acute Myeloid Leukaemia